Business
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform TechnologyAPVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform TechnologyAPVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate CancerSEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc. (\"Aptevo\" or the \"Company\") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ platform, today announced that it has expanded its ADAPTIR bispecific platform technology to include a new multi-specific platform technology, ADAPTIR-FLEX™. Aptevo also announced that it has developed a new bispecific candidate, APVO442, that uses ADAPTIR-FLEX platform technology. APVO442 is a unique T-cell engager designed to target PSMA (prostate specific membrane antigen) and CD3 with low affinity for the treatment of prostate cancer. Prostate cancer is one of the most common forms of cancer in men.ADAPTIR-FLEX expands Aptevo's ability to create novel therapeutic multi-specific candidates with the potential of exhibiting a wide variety of mechanisms of action. The new ADAPTR-FLEX platform technology enables the design of candidates that have modified affinity and valency to a target, which has the potential to improve specificity, tumor targeting, and therapeutic benefit with application to multiple hematologic and solid tumors. ADAPTIR-FLEX utilizes the same IgG-backbone and linkers found in ADAPTIR, but in a heterodimeric format, while retaining good manufacturability attributes and extended half-life that may enable improved dosing regimens in clinical development.Aptevo also announced that it has developed a new bispecific candidate, APVO442, that utilizes ADAPTIR-FLEX platform technology targeting PSMA and CD3 for the treatment of prostate cancer. There has been early clinical validation of the combination of PSMA x CD3 as a bispecific in clinical development. Aptevo designed the new bispecific candidate APVO442 to have two binding domains targeting PSMA, to potentially increase avidity (strength) of binding to the tumor antigen PSMA, with one binding domain to CD3 with reduced binding affinity to T cells demonstrated in vitro.\"We are very excited about the launch of our second platform technology, ADAPTIR-FLEX, which expands our capability to design candidates with multiple new mechanisms of a...